Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 3/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7857063 | 0.84 | PTGDR2 (0.56) | PTGDR2PTGDRKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL985213 | 0.82 | TSHR (0.44) | KMT2ASMN1; SMN2ALDH1A1PTGER4PTGER3 | |
| SCHEMBL830740 | 0.81 | KMT2A (0.60) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6089997 | 0.80 | PTGDR2 (0.50) | PTGDR2KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL5586090 | 0.80 | GABRA1 (0.41) | SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL9715056 | 0.79 | KDM4E (0.51) | KMT2ASMN1; SMN2ALDH1A1MEN1KDM4E | |
| SCHEMBL5259031 | 0.78 | PTGDR (0.44) | PTGDR2PTGDRKMT2AALDH1A1NPC1 | |
| SCHEMBL5259025 | 0.78 | PTGDR (0.44) | PTGDR2PTGDRKMT2AALDH1A1NPC1 | |
| SCHEMBL7805020 | 0.78 | PTGER4 (0.53) | ALDH1A1PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL10790494 | 0.77 | GABRA1 (0.44) | KMT2AALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | PTGDR2 4710/4885PTGDR 4558/4885KMT2A 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.